ABCB1 Genotyping for Microtubule-Stabilizing Agent Toxicity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for administering taxanes and other microtubule-stabilizing agents often result in severe adverse effects such as neutropenia and peripheral neuropathy, with limited ability to predict which patients will experience these side effects, leading to suboptimal treatment outcomes.
Innovation Solution
Identifying polymorphisms in the ABCB1 gene, specifically 1236C>T, 2677G>T/A, and 3435C>T, to predict an increased risk of adverse effects, allowing for personalized modifications in treatment dosing and scheduling, such as reduced dosages or prolonged infusion times, and the use of colony-stimulating factors to mitigate neutropenia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard dosing of taxanes is administered, then antitumor activity is achieved, but severe adverse effects such as neutropenia and peripheral neuropathy occur
Solution Approach 1:
The patent performs ABCB1 genotyping before taxane administration to identify patients at high risk for adverse effects. This preliminary genetic assessment allows for proactive treatment modification (dose reduction or alternative therapy) before toxicity occurs, resolving the contradiction by predicting and preventing harmful effects while maintaining effective antitumor treatment for suitable candidates
Solution Approach 2:
The patent modifies treatment parameters (dosage, scheduling) based on ABCB1 genotype results. For patients with high-risk genotypes, the dosage is reduced or scheduling is adjusted, which changes the treatment parameters to balance antitumor efficacy with reduced toxicity, thereby resolving the contradiction between achieving reliable antitumor activity and minimizing adverse effects
2Object-affected harmful factors
If dose-limiting toxicity is avoided by reducing taxane dosage, then adverse effects are reduced, but treatment efficacy may be compromised
Solution Approach 1:
By performing ABCB1 genotyping before treatment, the patent identifies which patients are at risk for dose-limiting toxicity in advance. This allows clinicians to proactively adjust dosage or scheduling for high-risk patients while maintaining standard effective dosing for low-risk patients, thereby avoiding adverse effects without compromising treatment efficacy for the appropriate patient population
Solution Approach 2:
The patent applies different treatment strategies to different patient subgroups based on their ABCB1 genotype. High-risk patients receive modified dosing to minimize toxicity, while low-risk patients receive standard effective dosing. This localized, personalized approach ensures each patient receives the optimal balance between efficacy and safety for their specific genetic profile
3Object-affected harmful factors
If cumulative peripheral neuropathy is prevented by reducing cumulative dose, then adverse effects are reduced, but antitumor activity is diminished
Solution Approach 1:
The patent identifies patients at high risk for cumulative peripheral neuropathy through ABCB1 genotyping before treatment begins. This preliminary identification allows for proactive dosage modification or alternative therapy selection for high-risk patients, preventing cumulative neuropathy while maintaining adequate antitumor activity through personalized dosing strategies
Solution Approach 2:
The patent adjusts treatment parameters (cumulative dose, scheduling intervals) based on ABCB1 genotype. For high-risk patients, the cumulative dose is modified to prevent neuropathy while maintaining antitumor efficacy. For low-risk patients, standard cumulative dosing is maintained to ensure adequate antitumor activity, thus resolving the contradiction through genotype-guided parameter optimization
Data Source
AI summary
The present disclosure provides methods of identifying subjects having an increased likelihood of developing one or more adverse side effects resulting from administration of a microtubule-stabilizing agent. In particular examples, the method includes determining whether the subject has an ABCB1 predictive polymorphism for microtubule-stabilizing agent-induced toxicity, wherein the presence of such a polymorphism indicates that the subject has an increased risk of developing microtubule-stabilizing agent induced adverse effects. Examples of ABCB1 predictive polymorphisms include 2677G>T/A and 3435C>T. Also provided are methods of modifying microtubule-stabilizing agent therapy in a subject identified as having one or more ABCB1 predictive polymorphisms. Kits and isolated nucleic acid molecules that can be used in the disclosed methods are also provided.